Paraprobiotics as immunopotentiating agents of myelopoiesis

FLORENCIA GUTIERREZ; ANDRÉS DANIEL GRAMAJO; JORGE ARMANDO JIMENEZ AVALOS; HÉCTOR MAXIMILIANO IVIR; JULIO VILLENA; SUSANA ALVAREZ; SUSANA SALVA

Mar del Plata

Congreso; LXIII Reunión Anual de la Sociedad Argentina de Investigación Clínica, LXVI Reunión Anual de la Sociedad Argentina de Inmunología, Reunión Anual de la Sociedad Argentina de Fisiología; 2018

SAI-SAIC

Myelosuppression is the major dose-limiting toxicity of systemic cancer chemotherapy. At present, hematological rescue techniques are applied to reduce the chemotherapy-induced neutropenia that include new adverse effects. Probiotic lactic acid bacteria (LAB) have shown promise in the find of safe agents that can reduce myelosuppression. We demonstrated that the dietary supplementation with probiotic Lactobacillus rhamnosus CRL 1505 (Lr05) improve steady-state and emergency granulopoiesis, the respiratory innate immune response and the resistance against respiratory pathogens in immunosupressed hosts. While the viability of the LAB is an important factor to achieve optimal protective effects, it is possible to stimulate immunity using non-viable LAB. The aim of this work is to study the ability of paraprobiotics (cell fractions) from Lr05 to minimize myelosuppressive effects derived from chemotherapy. Adult Swiss-mice were orally treated with paraprobiotics: peptidoglycan (PG group) and cell wall (CW group), during 15 consecutive days (8µg/mice/day). On day 6, paraprobiotic-treated and untreated control mice received one intraperitoneally dose of cyclophosphamide (Cy) (150 mg/kg). Before Cy-injection, both PG and CW groups shown an increase of the peroxidase (Px) score in blood and the myeloid cells in BM compared with control (p